Eli Lilly faces more claims over diabetes treatment
A French company has brought additional claims of US$200 million against US pharmaceuticals giant Eli Lilly in an ICC arbitration begun last year over a collaborative research project to develop an insulin treatment for diabetes.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.